Lipitor Scripts Rebounding, Pfizer Says; Cholesterol Category Still Has Life
Executive Summary
Pfizer sees signs of a rebound in Lipitor (atorvastatin) prescriptions over the past six weeks, U.S. Pharmaceuticals President Pat Kelly said during Pfizer's June 17 analysts meeting in New York
You may also be interested in...
Tough Sell? Pfizer CEO Outlines Lipitor Game Plan For Generic Zocor
Pfizer's efforts to sustain growth for Lipitor in the face of forthcoming competition from generic versions of Merck's Zocor will focus on educating payers about atorvastatin's positive impact on overall healthcare costs relative to simvastatin, CEO Hank McKinnell said Jan. 4
Tough Sell? Pfizer CEO Outlines Lipitor Game Plan For Generic Zocor
Pfizer's efforts to sustain growth for Lipitor in the face of forthcoming competition from generic versions of Merck's Zocor will focus on educating payers about atorvastatin's positive impact on overall healthcare costs relative to simvastatin, CEO Hank McKinnell said Jan. 4
Combo Rx Product Market Potential Is Enhanced By Single Copay – Analysts
Combination drug products may have more market potential due to their copay advantage, sellside research analysts suggested April 1 at an IIR conference in Philadelphia